注射用生长抑素在大咯血中的应用

Application of somatostatin injection in massive hemoptysis

目的研究生长抑素治疗大咯血的效果及安全性,为今后该病的临床治疗提供可参考的依据。方法本研究选取惠州市博罗县人民医院2013年3月-2014年10月收治的50例患者为研究对象,按照入院顺序将其分为治疗组（n=25）和对照组（n=25）。治疗组给予注射用生长抑素治疗,对照组给予脑垂体后叶素治疗。比较两组临床疗效与不良反应情况。结果治疗组总有效率为96.0%,对照组总有效率为60.0%,治疗组明显高于对照组,差异有高度统计学意义（χ^2=7.969,P〈0.01）。治疗组不良反应发生率为16.0%,对照组不良反应发生率为56.0%,治疗组明显低于对照组,差异有高度统计学意义（χ^2=7.109,P〈0.01）。对照组生活质量总评分[（3.2±1.0）分]低于治疗组[（4.8±0.9）分],差异有统计学意义（t=4.946,P〈0.05）。结论注射用生长抑素可有效改善大咳血患者的临床症状,且不良反应发生率低,临床疗效确切,值得临床推广应用。

Objective To study the clinical effect and safety of somatostatin during the treatment of massive hemoptysis, provide a reference basis for the clinical treatment. Methods 50 patients with massive hemoptysis from March 2013 to October 2014 in the People＇s Hospital of Boluo County in Huizhou City, and they were divided into treatment group（n=25） and control group（n=25） according to admission order. Patients of the treatment group were treated with somatostatin for injection, and the control group was treated with pituitrin. The clinical efficacy and adverse reactions of patients in the two groups were compared. Results The total effective rate of the treatment group was 96.0%, the control group total effective rate was 60.0%, total effective rate of the treatment group was significantly higher than that of the control group, the difference was statistically significant（χ^2=7.969, P〈0.01）; incidence of adverse rate in the treatment group was 16.0%, the control group was 56.0%, the incidence of adverse of the treatment group was significantly lower than that of the control group, the difference was statistically significant（χ^2=7.109, P〈0.01）. The overall quality of life in the control group was（3.2±1.0） points, less than that of the treatment group [（4.8±0.9） points], the difference was statistically significant（t =4.946, P〈0.05）. Conclusion Somatostatin for injection can effectively improve the clinical symptoms of patients with large hemoptysis, and it has a low incidence of adverse reaction, good clinical efficacy, worthy of clinical application.